Advertisement

Topics

Medialink, Abiomed Company Profile

15:39 EST 23rd November 2017 | BioPortfolio


News Articles [35 Associated News Articles listed on BioPortfolio]

Abiomed: Abiomed gibt Umsatz von 132,8 Millionen USD (Anstieg um 29 %) für das zweite Quartal des Geschäftsjahres 2018 und einen Rekord-Einsatz bei Patienten in den USA (Anstieg um 33 %) bekannt

DANVERS (USA), 27. Oktober 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (http://www.abiomed.com/) (NASDAQ:ABMD), ein führender Anbieter bahnbrechender Herzunterstützungstechnologien, vermeldete heute ei.....

Abiomed: Abiomed erhält PMA-Genehmigung der FDA für Impella RP® für Rechtsherzinsuffizienz

DANVERS, Massachusetts, den 22. September 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), ein führender Anbieter innovativer Technologien zur Unterstützung und Wiederherstellung der Herzfunk.....

Abiomed: Neue Studie mit Impella 2.5® Herzpumpe von Abiomed belegt nachweislich Überlebensvorteil beim prä-PCI-Einsatz der Pumpe bei Patienten mit Herzinfarkt der linken Hauptkoronararterie

DANVERS, Mass., July 3, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc (https://www.globenewswire.com/Tracker?data=zcP6Pp1wrZjuaxvGJzjaNnW122S7e70gBaoTheOmgfL3TqkF-whzZACCnCdGsrPjCL1OCRo5tMYqz6yPsJejyw==)....

Abiomed: Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure

DANVERS, Mass., 2017-09-21 00:26 CEST (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U....

Abiomed: Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%

DANVERS, Mass., 2017-10-26 13:00 CEST (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2018 reven...

Abiomed: New Study with Abiomed's Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery

DANVERS, Mass., 2017-06-30 14:17 CEST (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the recent publica...

Israeli medtech startup gets $15M boost from Abiomed, other investors

A round of Series B financing led by Abiomed and venture capital firm Pitango brought in $15 million for Israeli medical devi -More- 

Abiomed's Impella heart pump wins FDA nod for right heart failure

Abiomed obtained premarket approval from the FDA for its percutaneous temporary ventricular support device, the Impella RP Sy -More- 

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Biventricular Impella placement via complete venous access.

Impella (Abiomed, Danvers, MA) is an effective option for emergent treatment of critical refractory cardiogenic shock. However, in patients who have inadequate peripheral arterial access, Impella for ...

Companies [7 Associated Companies listed on BioPortfolio]

Medialink, Abiomed

Abiomed Incorporated

Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES. The Company's portfolio of heart support and recovery products and services offer healthcare profes...

Medialink

Abiomed Inc.

Abiomed, Inc.

More Information about "Medialink, Abiomed" on BioPortfolio

We have published hundreds of Medialink, Abiomed news stories on BioPortfolio along with dozens of Medialink, Abiomed Clinical Trials and PubMed Articles about Medialink, Abiomed for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Medialink, Abiomed Companies in our database. You can also find out about relevant Medialink, Abiomed Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record